The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

CAR NK cells with CD28 costimulation improved cell persistence, antitumor activity

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Adding CD28 costimulation to cord blood-derived chimeric antigen receptor natural killer cells targeting CD70+ cancers significantly enhanced antitumor efficacy and long-term cytotoxicity of the CAR NK cells, according to researchers from MD Anderson Cancer Center.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

MD Anderson’s Boot Walk to End Cancer raises $1.4M

The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account